Recent 8-K filings for HRGN

• April 28, 2026, 7:59 PM ET other material materiality 0.70 positive item 7.01item 9.01

  Harvard Apparatus Regenerative Technology treats first patient in Phase 1 esophageal implant trial

  First patient treated with Cellspan Esophageal Implant (CEI) in Phase 1 clinical trial at Mayo Clinic.

• April 15, 2026, 7:59 PM ET debt materiality 0.60 neutral item 1.02item 9.01

  Harvard Apparatus receives $300K bridge loan from CEO Junli He at 8% interest

  Loan of $300,000 from Chairman/CEO Junli He; annual 8% fixed interest rate.

• January 6, 2026, 6:59 PM ET other material materiality 0.50 neutral item 1.01item 3.02item 9.01 ◈ Material Agreements

  Harvard Apparatus Regenerative Technology raises ~$0.7M in private placement of 411,765 shares at $1.70/share

  Sold 411,765 shares of common stock at $1.70 per share for aggregate proceeds of approximately $0.7 million.

• July 14, 2025, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 9.01

  Harvard Apparatus raises $2.0M via private placement of 1.25M shares at $1.60/share

  Sold 1,250,000 shares of common stock to accredited investors for aggregate proceeds of ~$2.0M.

• June 24, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.07

  Harvard Apparatus shareholders approve reverse stock split and declassification amendment at annual meeting

  Reverse stock split amendment approved; Board authorized to determine ratio and timing at discretion.

• April 14, 2025, 7:59 PM ET other material materiality 0.40 neutral item 4.01item 9.01

  Harvard Apparatus Regenerative Tech replaces auditor: Marcum resigns, CBIZ CPAs P.C appointed April 11, 2025

  Marcum LLP resigned as independent auditor effective April 11, 2025; Audit Committee approved CBIZ CPAs P.C. as successor the same day.

• November 6, 2024, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 9.01

  Harvard Apparatus Regenerative Technology signs exclusive global distribution deal with Health Regen through 2030

  Exclusive distribution of consumer health/dietary supplements from Nov 1, 2024 to Dec 31, 2030; auto-renews for 6 years if targets met.

• August 27, 2024, 7:59 PM ET leadership materiality 0.40 neutral item 5.02item 9.01 ◈ executive_change

  Harvard Apparatus Regenerative Technology appoints StellarS Capital CEO Mao Zhang to board

  Mao Zhang, Founder & CEO of multi-billion-dollar alternative asset manager StellarS Capital, appointed as independent Class I director effective Aug 26, 2024.

• August 21, 2024, 7:59 PM ET other material materiality 0.55 neutral item 1.01item 3.02item 9.01

  Harvard Apparatus raises $5.0M via private placement of 1.39M shares at $3.60/share

  Sold 1,388,888 shares to Stellars Capital at $3.60/share for approx $5.0 million.

• June 24, 2024, 7:59 PM ET other material materiality 0.10 neutral item 5.07

  Shareholders elect three directors, ratify auditor, and approve executive compensation at 2024 annual meeting

  David Green, Ting Li, and Ronald Packard elected as Class II directors for three-year terms.

• April 17, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 9.01 ◈ Material Agreements

  Harvard Apparatus Regenerative Technology raises $1.5M in private placement of 367,767 shares at $4.03/share

  Aggregate purchase price of $1.5 million for 367,767 shares at $4.03 per share in a private placement.

Executive changes

Materiality & sentiment trend

Max materiality 0.75 · Median 0.60 · Most common event other_material

1 positive 0 negative 10 neutral

source · HRGN on sec.gov